The University of Southampton
University of Southampton Institutional Repository

No significant molecular response in polycythemia vera patients treated with imatinib or interferon alpha

Jones, Amy V., Higley, Katherine, Curtis, Claire, Kreil, Sebastien, Zoi, Katerina, Hochhaus, Andreas, Reiter, Andreas, Oscier, David, Merber, Alec, Silver, Richard T. and Cross, Nicholas C.P. (2005) No significant molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood, 106, (11), p.113A.

Record type: Article


Imatinib mesylate and interferon alpha (rIFNa) have both been reported to induce remission in patients with polycythemia vera (PV), but until recently it has not been possible generally to gauge the depth of these responses due to the absence of a specific cytogenetic or molecular marker of the disease. Here we have used ARMS and pyrosequencing assays to detect and quantify the V617F JAK2 mutation in granulocytes or mononuclear cells from 111 PV patients, of whom 14 were undergoing treatment with imatinib (300–800 mg/day; median follow up 17 months; range 5–31), seven were undergoing treatment with rIFNa (dose range from 2MU three times/week to 3MU/day; median follow up 60 months; range 13–132), and 90 were untreated or treated only by phlebotomy, hydroxyurea or anagrelide (control group). Clinical responses in the 14 imatinib treated cases were none (NR; n=3), partial (PR; n=9) or complete (CR; n=2); responses in the seven rIFNa treated cases were PR (n=1) or CR (n=6). The V617F mutation was detected in all cases undergoing treatment with imatinib or rIFNa and in 82 (91%) of the control PV cases. The median percentage of mutated JAK2 alleles (%V617F) did not differ significantly between the imatinib treated cases (median 59%, range 8–91), the rIFNa treated cases (median 27%, range 19–87) or the V617F positive cases from the control group (median 53%, range 5–100). In the imatinib group, the median %V617F for cases with NR, PR and CR were 72% (44–89; n=3), 60% (30–91; n=9) and 15% (8 and 21; n=2), respectively. In the rIFNa treated group the single case with a PR had 87% V617F compared to a median of 26% (19–39) for the six cases in CR. Pretreatment samples were available for 9 of the imatinib treated cases. Of these, all seven of the NR or PR cases showed a marginal increase (median 1.2 fold, range 1.0–1.5) in the percentage of V617F alleles on treatment. In contrast, the two CR patients showed a 2–3 fold reduction in %V617F on treatment. We conclude that although PV patients may benefit from treatment with imatinib or rIFNa, molecular analysis indicates that responses are modest.

Full text not available from this repository.

More information

Published date: 16 November 2005
Additional Information: ASH Annual Meeting Abstracts, Oral Sessions. Abstract 373


Local EPrints ID: 60616
ISSN: 0006-4971
PURE UUID: 783125b0-a0d0-4363-864d-30bce01ccf49
ORCID for Nicholas C.P. Cross: ORCID iD

Catalogue record

Date deposited: 10 Nov 2008
Last modified: 17 Jul 2017 14:23

Export record


Author: Amy V. Jones
Author: Katherine Higley
Author: Claire Curtis
Author: Sebastien Kreil
Author: Katerina Zoi
Author: Andreas Hochhaus
Author: Andreas Reiter
Author: David Oscier
Author: Alec Merber
Author: Richard T. Silver

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.